| Similar Articles |
|---|
 |
American Family Physician
October 15, 2003
Morris & Tiller |
Ezetimibe for Hypercholesterolemia Ezetimibe is safe and effective for lowering LDL cholesterol and triglyceride levels, but has not been shown to affect patient-oriented outcomes.   |
American Family Physician
July 15, 2005
Lee Radosh |
STEPS: Colesevelam (WelChol) for Reduction of LDL Cholesterol Colesevelam lowers LDL cholesterol levels a small amount (7% to 16%) when used alone and provides additional cholesterol lowering when added to statin therapy. |
American Family Physician
January 15, 2001
Michael A. Crouch |
Effective Use of Statins to Prevent Coronary Heart Disease Primary and secondary prevention trials have shown that use of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (also known as statins) to lower an elevated low-density lipoprotein level can substantially reduce coronary events and death from coronary heart disease... |
Nurse Practitioner
July 2010
Kristine A. Scordo |
Treating antiretroviral-induced dyslipidemia in HIV-infected adults Studies indicate that HIV-infected patients (both males and females) may be at an increased risk for the development of cardiovascular disease |
American Family Physician
March 15, 2005
Lockman et al. |
Treatment of Cholesterol Abnormalities The relationship between coronary heart disease and elevated cholesterol levels has been recognized for many years, but now studies show an improvement in patient-oriented outcomes in patients receiving drug therapy. |
Chemistry World
May 2008
Derek Lowe |
In the pipeline The controversy over cholesterol drug Vytorin has been going on for months. Surveying the wreckage, my first thought is: what a terrible shame the whole affair is. |
Chemistry World
February 19, 2013
Andrew Turley |
Merck resolves Vytorin case for $688m Merck & Co has agreed to pay $688 million to settle claims that it failed to report clinical trial data relating to cholesterol brands Zocor (simvastatin) and Vytorin (ezetimibe, simvastatin). |
The Motley Fool
April 2, 2008
Michael P. Cecil |
Irrational Exuberance for Vytorin and Zetia? Drugmakers Merck and Schering-Plough certainly hoped data from the Enhance study would enhance the value and status of their blockbuster cholesterol-fighting drugs Zetia and Vytorin -- but its results did quite the opposite. |
The Motley Fool
January 17, 2008
Michael P. Cecil |
2 Sources of Trouble for Vytorin You know that a drug study has gone very, very bad when you can't find out its results without a congressional inquiry. |
The Motley Fool
July 22, 2008
Brian Orelli |
Drug Duo SEAS Disappointment -- Again After numerous disappointments this year, Merck and Schering-Plough continue their string of bad luck. |
Chemistry World
April 23, 2013
Phillip Broadwith |
Ireland picks preferred drugs Ireland has become the first country to identify lists of 'preferred drugs'. Ensuring patients use the best value-for-money drugs could save patients and taxpayers millions of euros, says the Irish Health Service Executive. |
Managed Care
December 2007
Ed Silverman |
Drugs to Plan For in 2008 There are not many traditional medications in the pipeline, and those that are in development probably won't make waves. |
Chemistry World
June 2009
Derek Lowe |
Column: In the pipeline The author wonders about pharmaceutical companies' motives for collaboration |
Chemistry World
April 8, 2009
Peter Mitchell |
Polypill promises? Tablets containing a combination of several drugs, known as "polypills," hit the headlines recently after Indian research suggested they could be just as effective as taking each medication separately. |
